Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
3
38%
Ph phase_3
5
63%

Phase Distribution

0

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(1)
Other(2)

Detailed Status

Completed5
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (37.5%)
Phase 35 (62.5%)

Trials by Status

terminated113%
unknown225%
completed563%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT03292484
completedphase_2

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

NCT03682770
completedphase_3

PALISADE Follow-on Study (ARC004)

NCT02993107
completedphase_3

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

NCT03126227
completedphase_3

AR101 Real-World Open-Label Extension Study

NCT03337542
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03292484Phase 3

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Completed
NCT03682770Phase 2

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Completed
NCT02993107Phase 3

PALISADE Follow-on Study (ARC004)

Completed
NCT03126227Phase 3

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

Completed
NCT03337542Phase 3

AR101 Real-World Open-Label Extension Study

Completed
NCT03703791Phase 3

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Terminated
NCT02839226Phase 2

Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds

Unknown
NCT02602184Phase 2

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8